The study evaluated Heartzyme, the new systemic oral enzyme, in a small group of participants. Researchers measured C-reactive protein levels as an indication of the presence of inflammation.
Before treatment with Heartzyme the patients recruited had increased levels of C-reactive protein. Over an 8-week period, the C-reactive protein levels were reduced to normal levels.
Recent studies have linked inflammation to a wide variety of diseases including diabetes, cardiovascular disease and some cancers.
“For years researchers were convinced that oxidative damage was the sole culprit in many of these killers, now we know that chronic inflammation caused by smoking, excessive cholesterol and lingering infections can be equally as dangerous,” said Dr Martin, director of research and development at the company.
Dr Martin went on to say: “We at Martin Nutraceuticals are convinced that our enzyme formulas combined with our powerful anti-oxidant blend can reduce free radicals and low grade inflammation in the body thereby reducing the risk of North America’s major causes of death.”